Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2567437 | Pulmonary Pharmacology & Therapeutics | 2010 | 4 Pages |
Abstract
Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. With the increasing availability of other classes of drugs, this has limited the use of xanthnes. Doxofylline is a xanthine molecule that appears to be both bronchodilator and anti-inflammatory with an improved therapeutic window over conventional xanthines such as theophylline and the evidence supporting the effects of doxofylline in the treatment of lung diseases is discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Clive P. Page,